1stOncology™: Cancer Intelligence Service – Page 7774 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Gamida Cell to Present Corporate Highlights at the Oppenheimer 32nd Annual Healthcare Conference

On March 10, 2022 Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, reported that company management will present its corporate highlights at the upcoming Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022 at 2:00 p.m. ET (Press release, Gamida Cell, MAR 10, 2022, View Source [SID1234609930]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The webcast will be available on the "Investors & Media" section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days following the event.

Puma Biotechnology Announces $10 Million Private Placement

On March 10, 2022 Puma Biotechnology, Inc. (the Company) (Nasdaq: PBYI), a biopharmaceutical company, reported that it has entered into a securities purchase agreement with Alan H Auerbach, the Company’s Chief Executive Officer, President and Chairman of the Board, as well as a fund of Athyrium Capital Management, LP, a specialized asset management company focused on opportunities in the global healthcare sector, in connection with the sale in a private placement of 3,584,228 shares of common stock at a purchase price of $2.79 per share, which was the closing price of the common stock on the Nasdaq Global Select Market on the date of the securities purchase agreement (Press release, Puma Biotechnology, MAR 10, 2022, View Source [SID1234609929]). Gross proceeds to the Company will be approximately $10 million before deducting any offering expenses. The Company plans to use the net proceeds from the private placement primarily for general corporate purposes.

The private placement is expected to close on March 10, 2022, subject to the satisfaction of customary closing conditions. Additional details regarding the private placement will be included in a Form 8-K to be filed by the Company with the Securities and Exchange Commission (SEC).

The shares of common stock being sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable in connection with the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Perimeter Medical Imaging AI Announces its Participation in Multiple Upcoming Industry Conferences and Events

On March 10, 2022 Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, reported that it will participate in the following upcoming industry events and conferences (Press release, Perimeter Medical Imaging AI, MAR 10, 2022, View Source [SID1234609928]):

SSO 2022 – Society of Surgical Oncology’s International Conference on Surgical Cancer Care in Dallas, TX from March 9-12, 2022.
Spotlight Presentation: "A New Paradigm for Intraoperative Margin Visualization with OCT + Future AI" on Friday, March 11, 2022 at 12-12:15 pm CT by Dr. Beth Dupree and Dr. Amelia Tower. Learn more.
NCoBC 2022 – National Consortium of Breast Centers’ 31st Interdisciplinary Breast Center Conference in Las Vegas, NV from March 11-16, 2022. Learn more.
ASBrS 2022 – 23rd Annual Meeting of the American Society of Breast Surgeons in Las Vegas, NV from April 6-10, 2022.
Breakfast Symposium: "OCT + Future AI: Changing the Paradigm for Intraoperative Margin Visualization" on Friday, April 8, 2022 from 6:15-7:45 am PT by Dr. Richard Fine (Moderator), Dr. Amelia Tower, and Dr. Maryam Elmi. Learn more.
The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the "Investors" section of Perimeter’s website at View Source When available, webcasts will be posted for replay following the event.

RefleXion Raises $80 Million to Broaden Cancer Treatment Options

On March 10, 2022 RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* for all stages of cancer, reported the close of an $80 million equity financing (Press release, RefleXion Medical, MAR 10, 2022, View Source [SID1234609927]). In addition to participation from RefleXion’s existing investors, the company also welcomes investments from Ascension Ventures, Catalio Capital Management, Sixty Degree Capital and Hillenbrand Capital Partners.

"RefleXion’s breakthrough technology holds the potential to expand the reach of radiotherapy to late-stage cancers where five-year survival is less than 31%," said Tara Butler, M.D., senior managing director of Ascension Ventures. "We believe wholeheartedly in their goals of improving outcomes for these patients, and in prioritizing the availability of BgRT at community hospitals thereby enabling patients to receive their cancer treatment without traveling long distances."

Existing RefleXion investors that participated in the round include TPG’s The Rise Fund, KCK Group, PSP Investments, T. Rowe Price, Ally Bridge Partners, Venrock, and global pharmaceutical leaders, Pfizer Ventures and Johnson & Johnson Innovation, JJDC Inc.

BgRT is the first and only technology designed to transform an injected radiotracer into a unified motion management solution that overcomes the technical limitations currently restricting radiotherapy use to one or two tumors. RefleXion’s BgRT recently received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for use in lung tumors because of its potential to detect and then immediately treat moving targets. The company aims to one day scale BgRT to treat all visible cancer sites to create a new treatment option for patients with metastatic disease.

"The steadfast belief in RefleXion’s vision by our investor syndicate gives us the runway to drive hard and fast toward developing our platform for indications where radiotherapy was previously considered palliative only," said Todd Powell, president and CEO of RefleXion. "In just under a year, we have gained experience with image-guided radiotherapy by delivering nearly 2,000 patient treatments, successfully completed our feasibility study, secured an additional key radiopharmaceutical agreement, and expanded our commercial footprint."

"These important milestones lay the foundation for our future introduction of biology-guided radiotherapy," continued Powell.

BioCurity Pharmaceuticals Inc. (‘BioCurity’ or ‘Company’) Announces Presentation at ACRO Summit 2022 on Sensitizing Head and Neck Cancer to Radiation Using the Company’s Cerium Oxide Nanoparticles

On March 10, 2022 BioCurity, a preclinical biotech company focused on developing novel mechanism-based nanoparticle drugs designed to transform radiation therapy for cancer patients worldwide, reported the Company’s presentation at the American College of Radiation Oncology (ACRO) 2022 Summit on March 11, 2022, from 12:00-1:00pm EST at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida (Press release, BioCurity Pharmaceuticals, MAR 10, 2022, View Source [SID1234609926]). Details of the presentations are as follows:

Title: Harnessing Cerium Oxide Nanoparticles Combined with Tolfenamic Acid to Sensitize Head and Neck Cancer to Radiation
Session: Poster Walk with Professors – Bonnet
Presenter: Cheryl Baker, PhD, Scientific Co-Founder, BioCurity

The agenda for the ACRO 2022 Summit can be found here.

"Our IV and topical drug candidate consistent with positive preclinical data in lead indications such as head and neck, lung, and breast cancer was demonstrated to prevent radiation side effects without impairing the effectiveness of radiation killing cancer cells and shrinking tumors. BioCurity’s discovery could have a material positive impact for the millions of cancer patients that undergo radiation therapy annually. Approximately 70% of head and neck cancer patients treated with radiation therapy will develop severe oral mucositis, limiting their ability to eat or drink. We look forward to sharing our positive preclinical data with the leaders in radiation oncology at ACRO this week," said Dr. Cheryl Baker, PhD, Scientific Co-Founder, and a Board Member of BioCurity.

About Cerium Oxide Nanoparticles

The production of hydrogen peroxide, a Reactive Oxygen Species (ROS) from radiation is a critical function for how radiation damages the DNA of cells of the tissue it passes through. BioCurity’s cerium oxide nanoparticles possess fast catalase activity in a normal tissue’s neutral pH environment and reduces radiation-induced hydrogen peroxide to molecular oxygen, thereby preventing radiation damage of normal tissue. BioCurity’s cerium oxide nanoparticles also possess superoxide dismutase activity in a cancerous tissue’s acidic pH environment and converts superoxide to hydrogen peroxide, thereby enhancing radiation-induced ROS damage of cancerous tissue.

BioCurity’s extensive preclinical studies in models of head and neck, lung, breast, pancreatic, prostate, and colorectal cancer show cerium oxide nanoparticles are regenerative and are not consumed in the reaction. Administration of cerium oxide nanoparticles at 1,000 times the effective dose did not produce toxicity in a small animal model.